According to researchers at the H. Lee Moffitt Cancer Center & Research Institute, men with a mutation in their VAC14 gene are more susceptible to Docetaxil chemotherapy induced neuropathy and nerve pain. This debilitating side effect results from damage to the peripheral nerves and is felt by the man as weakness, numbness and pain most [...]
Family history and genetics. Prostate cancer is often referred to as a family disease. Is it and what does this actually mean? Malecare's Advanced Prostate Cancer Program Director, Joel Nowak, interviews Dr. Lorelei A. Mucci. Dr. Mucci is an epidemiologist specializing in prostate cancer. She works at the Harvard University School of Public Health in Boston, Massachusetts. [...]
We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]
The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]
In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]
Making treatment decisions once you have been diagnosed with prostate cancer is difficult. Often, it is impossible to accurately and reliably be able to predict the eventual course of the cancer. Prostate cancer, besides being one of the slower growing cancers, is also one of the deadliest. So good, informed decisions are vital. The original [...]
The possibility of having incontinence as a side effect from all of the primary prostate cancer treatments is significant. Incontinence is not an either or thing as the degree of incontinence varies from individual to individual. Those men having significant levels of inconvenience find that their quality of life is significantly damaged in some cases [...]
The cost of Enzalutamide (Xtandi) in the United States is being challenged by Knowledge Ecology International (KEI), a public interest advocacy group. The average US wholesale price of Xtandi in 2015 was $88 per capsule. That can add up to $129,000 annual cost per man. There are significant issues related to high costs of treatment. [...]
Nizoral (ketoconazole, keto) is an older drug that has been used as a part of hormone therapy (ADT) for many years. Keto, which is an inexpensive anti-fungal drug had been used for many years as an inhibitor of adrenal androgen synthesis as is abiriterone (Zytiga). Ztiga has been shown to be more effective, however, it [...]
I recently returned home from the American Association of Cancer Researchers (AACR) annual meeting held in New Orleans, La. The meeting was, as usual fantastic, but this years conclusion was by far the best I have experienced. The meeting’s closing session was reserved for remarks about the cancer "moonshot" initiative from Vice President Joe Biden. [...]
